IDEXX Laboratories, Inc. (IDXX) Stock

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

IDEXX Laboratories, Inc. is led by CEO Jonathan J. Mazelsky, employs 11,000 people, headquartered in Westbrook, US, publicly traded since 1991.

IDEXX Laboratories, Inc. (IDXX) stock trades at $569.77 with a market capitalization of $44.95B. The stock is valued at a price-to-earnings (P/E) ratio of 41.12, price-to-book of 27.81, price-to-sales of 10.17. Over the past 52 weeks the stock has ranged between $424.48 and $769.98, and currently trades 26.0% below its 52-week high.

On profitability, IDEXX Laboratories, Inc. generates a return on equity (ROE) of 72.91% — well above the market average, a sign of a high-quality business, return on capital employed of 84.68%, an operating margin of 31.60%, a net profit margin of 24.63%.

In its most recent fiscal year, IDEXX Laboratories, Inc. reported annual revenue of $4.3B, net profit of $1.1B, revenue has compounded at 9.7% a year over the last five years, profit at 12.7% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.71, a current ratio of 1.17, total assets of $3.4B, $180.0M in cash and equivalents.

IDXX has an average daily trading volume of 652,327 shares, a beta of 1.54 (more volatile than the overall market).

Official website: www.idexx.com